SG Americas Securities LLC Buys 111,391 Shares of Denali Therapeutics Inc. $DNLI

SG Americas Securities LLC raised its stake in shares of Denali Therapeutics Inc. (NASDAQ:DNLI) by 291.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 149,592 shares of the company’s stock after buying an additional 111,391 shares during the quarter. SG Americas Securities LLC’s holdings in Denali Therapeutics were worth $2,470,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of DNLI. Tudor Investment Corp ET AL increased its holdings in shares of Denali Therapeutics by 1.7% during the third quarter. Tudor Investment Corp ET AL now owns 56,368 shares of the company’s stock valued at $818,000 after acquiring an additional 920 shares in the last quarter. E Fund Management Co. Ltd. boosted its stake in Denali Therapeutics by 12.8% in the 2nd quarter. E Fund Management Co. Ltd. now owns 13,612 shares of the company’s stock worth $190,000 after purchasing an additional 1,543 shares in the last quarter. State of New Jersey Common Pension Fund D grew its position in Denali Therapeutics by 1.3% during the 3rd quarter. State of New Jersey Common Pension Fund D now owns 139,663 shares of the company’s stock valued at $2,028,000 after purchasing an additional 1,783 shares during the last quarter. California State Teachers Retirement System increased its stake in Denali Therapeutics by 1.5% during the 2nd quarter. California State Teachers Retirement System now owns 119,327 shares of the company’s stock valued at $1,669,000 after purchasing an additional 1,792 shares in the last quarter. Finally, Headlands Technologies LLC purchased a new position in Denali Therapeutics in the second quarter worth about $26,000. 92.92% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the stock. The Goldman Sachs Group increased their price target on shares of Denali Therapeutics from $35.00 to $40.00 and gave the company a “buy” rating in a report on Thursday, March 26th. Stifel Nicolaus boosted their price target on Denali Therapeutics from $34.00 to $41.00 and gave the stock a “buy” rating in a research note on Thursday, March 26th. Robert W. Baird raised their price target on shares of Denali Therapeutics from $29.00 to $32.00 and gave the company an “outperform” rating in a report on Thursday, March 26th. UBS Group began coverage on shares of Denali Therapeutics in a report on Wednesday, January 7th. They set a “buy” rating for the company. Finally, Morgan Stanley raised their target price on shares of Denali Therapeutics from $40.00 to $42.00 and gave the stock an “overweight” rating in a report on Thursday, March 26th. Two research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $34.82.

Insiders Place Their Bets

In other Denali Therapeutics news, insider Alexander O. Schuth sold 17,218 shares of the company’s stock in a transaction dated Tuesday, January 6th. The stock was sold at an average price of $16.50, for a total value of $284,097.00. Following the completion of the sale, the insider owned 282,828 shares in the company, valued at $4,666,662. This represents a 5.74% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Ryan J. Watts sold 35,198 shares of Denali Therapeutics stock in a transaction dated Tuesday, January 6th. The shares were sold at an average price of $16.50, for a total value of $580,767.00. Following the transaction, the chief executive officer directly owned 296,833 shares in the company, valued at approximately $4,897,744.50. The trade was a 10.60% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 12.50% of the stock is currently owned by company insiders.

Denali Therapeutics Stock Performance

DNLI opened at $20.65 on Friday. The company’s 50 day moving average is $20.49 and its 200 day moving average is $18.05. The company has a current ratio of 9.16, a quick ratio of 9.16 and a debt-to-equity ratio of 0.01. The company has a market cap of $3.27 billion, a price-to-earnings ratio of -6.95 and a beta of 1.10. Denali Therapeutics Inc. has a 12-month low of $10.57 and a 12-month high of $23.77.

Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings results on Thursday, February 26th. The company reported ($0.73) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.02. During the same quarter in the prior year, the company earned ($0.67) earnings per share. On average, equities research analysts predict that Denali Therapeutics Inc. will post -2.71 EPS for the current year.

About Denali Therapeutics

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.